Charles River Laboratories International (CRL) revenue

Revenue · fiscal 2025
$4.02B

Charles River Laboratories International (CRL) reported revenue of $4.02B in fiscal 2025 (the year ended December 31, 2025). That is 0.9% lower than the $4.05B of fiscal 2024. Figures as of 18 Nov 2026, 07:29 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$4.02B
Change on fiscal 2024
−0.9%
Growth, 5 years
+6.5% a year
Growth, 10 years
+11.4% a year
Highest on record
$4.13Bfiscal 2023
Lowest on record
$1.13Bfiscal 2012
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Charles River Laboratories International revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 6.5% a year; over ten years the rate was 11.4% a year. Across the 18 fiscal years on record (2008–2025), the highest was $4.13B in fiscal 2023 and the lowest $1.13B in fiscal 2012.

History · 18 fiscal years

Revenue by fiscal year

Charles River Laboratories International revenue, year by year

Charles River Laboratories International (CRL) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$4.02B 0.9% down
2024$4.05B 1.9% down
2023$4.13B 3.9% up
2022$3.98B 12.3% up
2021$3.54B 21.1% up
2020$2.92B 11.5% up
2019$2.62B 15.7% up
2018$2.27B 22.0% up
2017$1.86B 10.5% up
2016$1.68B 23.3% up
2015$1.36B 5.1% up
2014$1.30B 11.3% up
2013$1.17B 3.2% up
2012$1.13B 1.1% down
2011$1.14B 0.8% up
2010$1.13B 3.3% down
2009$1.17B 9.5% down
2008$1.30B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Charles River Laboratories International and comparable companies
CompanyRevenueFiscal year
Medpace Holdings MEDP$2.53B2025
Revvity RVTY$2.86B2025
Exelixis EXEL$2.32B2025
Charles River Laboratories International CRL$4.02B2025
Neurocrine Biosciences NBIX$2.86B2025
Ascendis Pharma ASND€720.13M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CRL

Charles River Laboratories International, figure by figure

Charles River Laboratories International (CRL) overview: price, valuation and scorecardAll health care companies by market value

Charles River Laboratories International revenue: questions and answers

What is Charles River Laboratories International's revenue?

Charles River Laboratories International (CRL) reported revenue of $4.02B in fiscal 2025 (the year ended December 31, 2025). That is 0.9% lower than the $4.05B of fiscal 2024.

What is the growth rate of Charles River Laboratories International's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 6.5% a year; over ten years the rate was 11.4% a year.

What are the highest and lowest revenue figures on record for Charles River Laboratories International?

Across the 18 fiscal years on record (2008–2025), the highest was $4.13B in fiscal 2023 and the lowest $1.13B in fiscal 2012.

How is Charles River Laboratories International's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Charles River Laboratories International (CRL) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/CRL/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.